Article

KalVista wins grant for DME treatment

KalVista Pharmaceuticals has received a £2.4 million grant to accelerate development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
Related Content
ASCRS 2025: Companies share preview of data and presentations scheduled for 2025 annual meeting
April 25th 2025

ASCRS 2025: Companies share preview of data and presentations scheduled for 2025 annual meeting

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325
April 25th 2025

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

(Image credit: AdobeStock/MarekPhotoDesign.com)
April 24th 2025

(Part 2) From ophthalmology’s lockdown to lasting change: The pandemic habits that stuck

(Image credit: AdobeStock/concept w)
April 24th 2025

(Part 1) From ophthalmology’s lockdown to lasting change: Five Aprils ago

© 2025 MJH Life Sciences

All rights reserved.